[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371805-105":59,"doc-detail-371805-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clonal-hematopoiesis-and-risk-of-nonmyeloid-subsequent-malignant-neoplasms-after-autologous-hematopoietic-cell-transplantation","Clonal hematopoiesis and risk of nonmyeloid subsequent malignant neoplasms after autologous hematopoietic cell transplantation","","Clonal hematopoiesis (CH) after autologous hematopoietic cell transplantation (HCT) and its relationship with nonmyeloid subsequent malignant neoplasms (SMNs) were evaluated. A retrospective cohort study included 1931 consecutive HCT patients treated at a single center from 2010–2016. Pre-HCT mobilized blood DNA was sequenced to identify CH variants with VAF ≥2%, and the primary endpoint was 8-year cumulative incidence of nonmyeloid SMNs. CH increased 8-year nonmyeloid SMN incidence (15.1% vs 7.2%) with risk rising by VAF and remained independently significant in multivariable models, alongside worse survival driven by higher nonrelapse mortality.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clonal-hematopoiesis-and-risk-of-nonmyeloid-subsequent-malignant-neoplasms-after-autologous-hematopoietic-cell-transplantation/371805/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clonal-hematopoiesis-and-risk-of-nonmyeloid-subsequent-malignant-neoplasms-after-autologous-hematopoietic-cell-transplantation/371805.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address?","Question",{"text":112,"@type":113},"The study examines whether clonal hematopoiesis (CH) is associated with the risk of nonmyeloid subsequent malignant neoplasms (SMNs) after autologous hematopoietic cell transplantation (HCT).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was CH measured in the study?",{"text":117,"@type":113},"DNA from pre-HCT mobilized blood products was sequenced to identify CH variants, using a variant allele frequency (VAF) threshold of at least 2%.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about CH and nonmyeloid SMN risk?",{"text":121,"@type":113},"Patients with CH had a higher 8-year cumulative incidence of nonmyeloid SMNs than those without CH (15.1% vs 7.2%), and risk increased with VAF. CH was also an independent risk factor in multivariable analysis and was linked to worse survival mainly due to higher nonrelapse mortality.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371805,1790229320,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","JNCI: Journal of the National Cancer Institute, 2025, 117(9), 1925–1933  \n[https://doi.org/10.1093/jnci/djaf181](https://doi.org/10.1093/jnci/djaf181)  \nAdvance Access Publication Date: July 10, 2025  \nArticle  \nClonal hematopoiesis and risk of nonmyeloid subsequent malignant neoplasms after autologoushematopoietic cell transplantation  \nJune-Wha Rhee , MD1, Sitong Chen, MPH2, Raju Pillai , MD3, Alysia Bosworth , BA2, Artem Oganesyan , MD2 Emma Grigorian , BA2, Liezl Atencio, MD2, Caitlyn Estrada , BS2, Mareen Kassabian, BA2, Lanie Lindenfeld, MA2  \nRusha Bhandari , MD, MS2, Scott Goldsmith , MD4, Michael Rosenzweig, MD4, Alex F. Herrera, MD4, Matthew G. Mei , MD4, Ryotaro Nakamura, MD4, F. Lennie Wong , PhD2, Stephen J. Forman, MD4, Saro H. Armenian , DO, MPH􀀃 ,2  \n1Department of Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, United States 2Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA, United States 3Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA, United States  \n4Department of Hematology & Hematopoietic Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, United States  \n􀀃 Corresponding author: Saro H. Armenian, DO, MPH, Department of Population Sciences, City of Hope Comprehensive Cancer Center, 1500 East Duarte Rd, Duarte, CA 91010, United States ([sarmenian@coh.org](sarmenian@coh.org))  \nAbstract  \nBackground: The association between clonal hematopoiesis (CH) and nonmyeloid subsequent malignant neoplasms (SMNs) after autologous hematopoietic cell transplantation (HCT) has not been explored.  \nMethods: This was a retrospective cohort study of 1931 consecutive patients who underwent HCT between 2010 and 2016 at a single center. DNA from pre-HCT mobilized blood products was sequenced to identify CH variants (variant allele frequency [VAF] ≥2%) . The primary outcome was 8-year(y) cumulative incidence of nonmyeloid SMNs. Multivariable regression analysis was used to evaluate the association between CH and nonmyeloid SMNs, as well as cause-specific mortality.  \nResults: Median age at HCT was 58.8 y (range ¼ 18.4-78.1 y); 389 patients (20.1% of the cohort) had at least 1 CH variant and 94 (4.9%) had ≥2 variants. The 8 y cumulative incidence of nonmyeloid SMNs was significantly higher in patients with CH compared with those without (15.1% vs 7.2%, P \u003C .001), and increased by VAF: 7.2%(VAF \u003C2%), 14.0%(VAF 2% to \u003C10%), 19.4%(VAF ≥10%); P ¼ .001. Patients with CH had a 2-fold increased risk of nonmyeloid SMNs (standardized incidence ratio ¼ 1.9), compared with the general population. In multivariable analysis, CH was an independent and significant risk factor for nonmyeloid SMNs (hazard ratio [HR] ¼ 1.72, 95% confidence interval [CI] ¼ 1.15 to 2.59) . Finally, patients with CH had significantly worse survival, primarily due to the higher risk of nonrelapse mortality (HR ¼ 2.97, 95% CI ¼ 1.90 to 4.64) .  \nConclusions: CH was significantly associated with the risk of nonmyeloid SMNs after HCT, and the magnitude of association increased by VAF. Clonal hematopoiesis may serve as a biomarker for identifying HCT survivors at higher risk for developing nonmyeloid SMNs.  \nIntroduction  \nAutologous hematopoietic cell transplantation (HCT) is a highly effective treatment for eligible patients with plasma cell dyscrasias (PCD) or relapsed/refractory lymphoma, resulting ina growing number of long-term survivors.1 , 2 However, these HCT survivors are at higher risk of developing subsequent malignant neoplasms (SMNs) compared with age- and sexmatched individuals in the general population, attributed in part to the cumulative genotoxic effects of pre-HCT and HCTrelated therapies (eg, chemotherapy [alkylators, topoisomerase inhibitors], radiotherapy [RT]) .3 ,4 Among HCT survivors, SMNs have emerged as the leading cause of late nonrelapse mortality,5-9 and this has coincided with a notable increase in older patients referred for autologous H","cbCaikeOZSiO37Q5","https://ap.wps.com/l/cbCaikeOZSiO37Q5","pdf",1168670,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What question does the study address?\",\"answer\":\"The study examines whether clonal hematopoiesis (CH) is associated with the risk of nonmyeloid subsequent malignant neoplasms (SMNs) after autologous hematopoietic cell transplantation (HCT).\"},{\"question\":\"How was CH measured in the study?\",\"answer\":\"DNA from pre-HCT mobilized blood products was sequenced to identify CH variants, using a variant allele frequency (VAF) threshold of at least 2%.\"},{\"question\":\"What did the results show about CH and nonmyeloid SMN risk?\",\"answer\":\"Patients with CH had a higher 8-year cumulative incidence of nonmyeloid SMNs than those without CH (15.1% vs 7.2%), and risk increased with VAF. CH was also an independent risk factor in multivariable analysis and was linked to worse survival mainly due to higher nonrelapse mortality.\"}]","Clonal hematopoiesis and risk of nonmyeloid subsequent malignant neoplasms after autologous hematopoietic cell transplantation | PDF",1790192908,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/556da36a1a0ec09f136d7d47605f1e67.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddb8bb179e99780698a16ff5910e8324.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f46544a854b7df784e91dca78c56f0d.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2cdff2cb25b77201a46c42eeb7322f12.webp",980,1287]